Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines
AssigneeThe Catholic University of America
InventorsVenigalla B. Rao, Pan Tao
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Catholic University of America
InventorsVenigalla B. Rao, Pan Tao
Estimating the term…
Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH2-terminal β-strand of F1 of Yersinia pestis is transplanted to the COOH-terminus of F1 of Yersinia pestis and the NH2-terminus sequence flanking the β-strand of F1 of Yersinia pestis is duplicated to eliminate polymerization but to retain the T cell epitopes. The mutated F1 is fused to the V antigen of Yersinia pestis to thereby form a fusion protein F1mut-V mutant, which produces a completely soluble monomer. The fusion protein F1mut-V is then arrayed on phage T4 nanoparticles via a small outer capsid protein, Soc, from a T4 phage or a T4-related phage. Both the soluble and T4 decorated F1mut-V provided approximately 100% protection to mice and rats against pneumonic plague evoked by high doses of Yersinia pestis CO92.
A recombinant protein comprising a mutated F1 antigen of Yersinia pestis, wherein the mutated F1 antigen of Yersinia pestis is developed from a native F1 antigen of Yersinia pestis by the following steps:
A method for producing a recombinant protein comprising the following steps:
Dependencies are inferred from the claim text.